Adenosine causes the release of active renin and angiotensin II in the coronary circulation of patients with essential hypertension

Journal of the American College of Cardiology

Volumn 33, Issue 6, 1999, Pages 1677-1684

  Virdis, Agostino ^a   Ghiadoni, Lorenzo ^a   Marzilli, Mario ^b   Orsini, Enrico ^b   Favilla, Stefania ^a   Duranti, Piero ^a   Taddei, Stefano ^a   Marraccini, Paolo ^b   Salvetti, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ADENOSINE; ANGIOTENSIN; BENAZEPRILAT; NITROPRUSSIDE SODIUM; RENIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ESSENTIAL HYPERTENSION; FEMALE; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ACETYLCHOLINE; ADENOSINE; ADULT; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOREARM; HEART CATHETERIZATION; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; INFUSIONS, INTRA-ARTERIAL; LASER-DOPPLER FLOWMETRY; MALE; MIDDLE AGED; NITROPRUSSIDE; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0033133531     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00078-9     Document Type: Article

References (42)

1. Dzau VJ. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 1989;7:933-6.
2. Campbell DJ. Circulating and tissue angiotensin system. J Clin Invest 1987;79:1-6.
3. Muller DN, Bohlender J, Hilgers KE, et al. Vascular angiotensin-converting enzyme expression regulates local angiotensin II. Hypertension 1997;29:98-104.
4. Lannoy LM, Danser AH, van Katz JP, et al. Renin-angiotensin system components in the interstitial fluid of the isolated perfused rat heart. Hypertension 1997;29:1240-51.
5. Danser AH. Local renin-angiotensin system. Mol Cell Biochem 1996;157:211-6.
6. Taddei S, Favilla S, Duranti P, Simonim N, Salvetti A. Vascular renin-angiotensin system and neurotransmission in hypertensive persons. Hypertension 1991;18:266-77.
7. Taddei S, Favilla S, Salvetti A. Active and inactive renin in human forearm of hypertensive patients. Can J Physiol Pharmacol 1991;69:1390-3.
8. Taddei S, Virdis A, Abdel-Haq B, et al. Indirect evidence for vascular uptake of circulating renin in hypertensive patients. Hypertension 1993;21:852-60.
9. Taddei S, Virdis A, Mattei P, Favilla S, Salvetti A. Angiotensin II and sympathetic activity in sodium-restricted essential hypertension. Hypertension 1995;25:595-601.
10. Taddei S, Salvetti A. Vascular tissue renin-angiotensin system in hypertensive humans. J Hypertens 1992;10 (Suppl 7):S165-72.
11. 2 adenosine receptor activation inhibits and stimulates renin secretion of rat renal cortical slices. J Pharmacol Exp Ther 1985;232:589-94.
12. Taddei S, Virdis A, Favilla S, Salvetti A. Adenosine activates a vascular renin-angiotensin system in hypertensive subjects. Hypertension 1992;19:672-5.
13. McKenzie JE, McCoy FP, Bockman EL. Myocardial adenosine and coronary resistance during increased cardiac performance. Am J Physiol 1980;239:H509-15.
14. Watkinson WP, Foley DH, Rubio R, Berne RM. Myocardial adenosine formation with increased cardiac performance in the dog. Am J Physiol 1979;296:H13-21.
15. Morganti A, Pelizzola D, Mantero F, et al. on behalf of the Italian Multicenter Study for Standardization of Renin Measurement. Immunoradiometric versus enzymatic renin assay: results of the Italian Multicenter comparative study. J Hypertens 1995;13:19-26.
16. Cushman DW, Cheung HS. Concentration of angiotensin converting enzyme in tissues of the rat. Biochem Biophys Acta 1971;250:261-5.
17. Zierler KL. Theory of arteriovenous concentration differences for measuring metabolism in steady and non-steady states. J Clin Invest 1961;40:2111-25.
18. 2 agonists in the conscious spontaneously hypertensive rat: a comparative study of three structurally distinct ligands. J Pharmacol Exp Ther 1991;259:1203-12.
19. Smits GJ, Kitzen JM, Perrone MH, Cox BF. Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation. Hypertension 1993;22:221-30.
20. Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol Rev 1976;56:1-56.
21. von Lutterotti N, Catanzaro DF, SealeyJE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. Circulation 1994;89:458-70.
22. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine: a paradigm shift? Circulation 1994;89:493-8.
23. Katz SA, Opsahl JA, Lunzer MM, Forbis LM, Hirsch AT. Effect of bilateral nephrectomy on active renin, angiotensinogen, and renin glycoforms in plasma and myocardium. Hypertension 1997;30:259-66.
24. Grinstead WC, Young BJ. The myocardial renin-angiotensin system: existence, importance, and clinical implications. Am Heart J 1992;123:1039-45.
25. Danser AHJ, Koning MMG, Admiraal PJJ, et al. Production of angiotensin I and II at tissue sites in intact pigs. Am J Physiol 1992;263:H429-37.
26. Sealey JE, Trenkwalder P, Gahnem F, Catanzaro D, Laragh JH. Plasma renin methodology: inadequate sensitivity and accuracy of direct renin assay for clinical applications compared with the traditional enzymatic plasma renin activity assay. J Hypertens 1995;13:27-30.
27. Westlin W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation 1988;77:130-9.
28. Linz W, Scholkens BA, Han YF. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J Cardiovasc Pharmacol 1986; Suppl 10:591-9.
29. Feldman MD, Ayers CR, Lehman MR, et al. Improved detection of ischemia-induced increases in coronary sinus adenosine in patients with coronary artery disease. Clin Chem 1992;38:256-62.
30. Pfeffer MA, Braunwald E, Moyè LA, et al. for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial (SAVE). N Engl J Med 1992;327:669-77.
31. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
32. Kober L, Torp-Pedersen C, Carlsen JE, et al. for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
33. Ambrosioni E, Borghi C, Magnani B for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
34. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
35. ISIS-4 Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
36. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
37. Nussberger J, Brunner DB, Waeber BW, Brunner HR. Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986;8:476-82.
38. Dahlof B, Pennert K, Hansson L. Reversal of LVH in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-100.
39. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
40. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of enalapril vs nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996;78:61-5.
41. Gottdiener JS, Reda DJ, Massie BM, et al. for the VA Cooperative Study Group on Antihypertensive Agents. Effects of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997;95:2007-14.
42. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997;95:1983-5.